The potential of omics technologies for the treatment of immune‐mediated inflammatory diseases

Anchang CG, Xu C, Raimondo MG, Atreya R, Maier A, Schett G, Zaburdaev V, Rauber S, Ramming A (2021)


Publication Type: Journal article, Review article

Publication year: 2021

Journal

Book Volume: 22

Article Number: 7506

Journal Issue: 14

DOI: 10.3390/ijms22147506

Abstract

Immune‐mediated inflammatory diseases (IMIDs), such as inflammatory bowel diseases and inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis), are marked by increasing worldwide incidence rates. Apart from irreversible damage of the affected tissue, the systemic nature of these diseases heightens the incidence of cardiovascular insults and colitis‐associated neo-plasia. Only 40–60% of patients respond to currently used standard‐of‐care immunotherapies. In addition to this limited long‐term effectiveness, all current therapies have to be given on a lifelong basis as they are unable to specifically reprogram the inflammatory process and thus achieve a true cure of the disease. On the other hand, the development of various OMICs technologies is consid-ered as “the great hope” for improving the treatment of IMIDs. This review sheds light on the pro-gressive development and the numerous approaches from basic science that gradually lead to the transfer from “bench to bedside” and the implementation into general patient care procedures.

Authors with CRIS profile

How to cite

APA:

Anchang, C.G., Xu, C., Raimondo, M.G., Atreya, R., Maier, A., Schett, G.,... Ramming, A. (2021). The potential of omics technologies for the treatment of immune‐mediated inflammatory diseases. International Journal of Molecular Sciences, 22(14). https://dx.doi.org/10.3390/ijms22147506

MLA:

Anchang, Charles Gwellem, et al. "The potential of omics technologies for the treatment of immune‐mediated inflammatory diseases." International Journal of Molecular Sciences 22.14 (2021).

BibTeX: Download